Palo Alto, Calif. – September 18, 2023 – Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) today announced the launch of Recor’s refreshed brand identity. Recor is preparing for its anticipated premarket application (PMA) approval from the U.S. Food and Drug Administration (FDA) of its Paradise™ Ultrasound Renal Denervation (RDN) system.
The new look is an enlivened interpretation of the brand’s legacy, evolving the company logo, color palette and design elements to reflect a significant step forward. The Recor brand’s bold updated logo and warm colors make a strong statement, projecting the company’s confidence and vigor as a new stage in the business takes shape. Today’s brand unveiling also included refreshed social media visuals; the update will extend to a new website and other assets in the coming months.
“Recor’s story is one of unbridled enthusiasm, commitment and perseverance toward our goal as we achieved CE-mark and now approach PMA approval. Our journey has led us to an evolution of our brand that reflects what makes us unique and our goal to address significant unmet needs for patients worldwide,” said Lara Barghout, President and Chief Executive Officer, Recor Medical. “Our team has developed branding that visually represents who we are, where we are headed, and the higher standard to which we’ve always held ourselves. We look forward to sharing our new brand as we embark on our next chapter of growth.”
In August, the FDA Circulatory Systems Devices Panel of the Medical Devices Advisory Committee reviewed clinical trial data and voted favorably on the safety, efficacy, and benefit-to-risk profile of the Paradise Ultrasound RDN system. Hypertension puts people at risk for heart disease and stroke, which are leading causes of death in the U.S.
1. National Center for Health Statistics. Multiple Cause of Death 2018–2021 on CDC WONDER Database. Accessed February 2, 2023.
About Recor Medical, Inc.
Recor Medical, headquartered in Palo Alto, Calif., a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., is a medical technology company focused on transforming the management of hypertension. Recor has pioneered the use of the Paradise Ultrasound Renal Denervation system for the treatment of hypertension. The Paradise system is an investigational device in the United States and Japan and bears the CE mark. Recor has reported positive outcomes in three independent, randomized, sham-controlled studies of the Paradise system in patients with mild-to-moderate and resistant hypertension. In addition, Recor has begun the Global Paradise System (“GPS”) Registry in the European Union and the UK, with plans to expand globally.
About Otsuka Medical Devices Co., Ltd.
Otsuka Medical Devices focuses on the global development and commercialization of medical care products including endovascular devices that provide new therapeutic options in areas where patient needs cannot be met through pharmaceutical or other conventional treatment. Otsuka Medical Devices Co., Ltd. is a subsidiary of Otsuka Holdings Co., Ltd. (www.otsuka.com/en), a global healthcare company listed on the Tokyo Stock Exchange (JP 4578).